P/E ratio for Supernus Pharmaceuticals (SUPN)

P/E ratio history for Supernus Pharmaceuticals from 2012 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Zogenix ZGNX	-6.56	-114.37%	🇺🇸 USA
United Therapeutics UTHR	19.1	-58.19%	🇺🇸 USA
Eli Lilly LLY	138	202.76%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.7	-67.85%	🇺🇸 USA
Abbott Laboratories ABT	39.3	-13.89%	🇺🇸 USA
Johnson & Johnson JNJ	11.0	-75.80%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.